Emergent BioSolutions Inc. (EBS) exhibits 56.1% gross margins and 8.9% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 6.6x enterprise multiple and 4.8% implied options volatility.
Sustained 56.1% gross profitability converts into 13.5% operating margin and 8.9% ROIC, outpacing sector cost of capital.
ROIC: 8.9% // GM: 56.1%YoY revenue trajectory of -28.8% paired with 2.80% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -28.8% // FCF YLD: 2.80%Altman Z-Score of 1.41 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 1.41 // F-SCORE: 8/9Trading at 7.0x trailing P/E (6.5x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 7.0x // EV/EBITDA: 6.6xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $7.22 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 7.1% net margins.
NET MARGIN: 7.1% // D/E: 1.09x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for EBS & activate live FRED threshold breach alerts.